Malignant tumor of biliary tract (disorder)
ABC-07- Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers
Year Started: 2015
• Archival paraffin-embedded tissue - a representative archival block of the tumour tissue from a biopsy or prior surgery. • Whole blood for ctDNA - will be collected at 4 time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression. • Whole blood for germline DNA- will be collected from patients pre-treatment (within 14 days prior to starting CisGem). • Serum samples (optional for trial sites)- will be collected a 4 different time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Freezer temperature logs | > 6 months |
Treatment records | 3 - 6 months |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Paraffin | Not applicable | 51 - 75% | |
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Plasma | -60°C to -85°C | Not applicable | 51 - 75% | ||
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% |
Malignant tumor of biliary tract (disorder)
ABC-03 -
Year Started: 2011
Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Outside EU access restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Quality indicators | 0 - 3 months |
Treatment records | 0 - 3 months |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Not applicable | 0 - 10% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Malignant tumor of biliary tract (disorder)
ABC-04
Year Started: 2012
Samples taken from the ABC-04 trial: A phase Ib study of cisplatin, gemcitabine and selumetinib in patients with advanced biliary tract cancers.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Outside EU access restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 0 - 3 months |
Followup records | 0 - 3 months |
Imaging data | 0 - 3 months |
Pathology records | 0 - 3 months |
Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Not applicable | 0 - 10% |
Malignant tumor of biliary tract (disorder)
ABC-07- Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (Copy 1)
Year Started: 2015
• Archival paraffin-embedded tissue - a representative archival block of the tumour tissue from a biopsy or prior surgery. • Whole blood for ctDNA - will be collected at 4 time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression. • Whole blood for germline DNA- will be collected from patients pre-treatment (within 14 days prior to starting CisGem). • Serum samples (optional for trial sites)- will be collected a 4 different time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Freezer temperature logs | > 6 months |
Treatment records | 3 - 6 months |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Paraffin | Not applicable | 51 - 75% | |
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Plasma | -60°C to -85°C | Not applicable | 51 - 75% | ||
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% |
Malignant tumor of biliary tract (disorder)
ABC-07- Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers
Year Started: 2015
• Archival paraffin-embedded tissue - a representative archival block of the tumour tissue from a biopsy or prior surgery. • Whole blood for ctDNA - will be collected at 4 time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression. • Whole blood for germline DNA- will be collected from patients pre-treatment (within 14 days prior to starting CisGem). • Serum samples (optional for trial sites)- will be collected a 4 different time points, Pre-treatment, end of cycle 4, completion of treatment and at 6 month follow up or at disease progression.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Freezer temperature logs | > 6 months |
Imaging data | 3 - 6 months |
Treatment records | 3 - 6 months |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Not applicable | 51 - 75% | ||
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Plasma | -60°C to -85°C | Not applicable | 51 - 75% | ||
Whole blood | -60°C to -85°C | Not applicable | 51 - 75% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Whole blood | -60°C to -85°C | Not applicable | 51 - 75% | ||
Tissue specimen | RT | Paraffin | Not applicable | 51 - 75% | |
Plasma | -60°C to -85°C | Not applicable | 51 - 75% | ||
Serum | -60°C to -85°C | Not applicable | 51 - 75% |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | Not applicable | 51 - 75% | ||
Tissue specimen | RT | Paraffin | Not applicable | 51 - 75% | |
Plasma | -60°C to -85°C | Not applicable | 51 - 75% | ||
Whole blood | -60°C to -85°C | Not applicable | 51 - 75% |